buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · May 1, 2023

Keywords

ClinConnect Summary

The RESTORE trial is a research study looking at new ways to help patients who have seizures after a cardiac arrest, known as refractory status epilepticus. The trial is exploring two different treatment approaches: one that aims to reduce the activity in the brain called "burst suppression" and another that focuses on stopping seizures. This study is important because it could lead to better care for patients who are in a coma after cardiac arrest and are not responding to standard treatments.

To participate in this trial, patients must be at least 18 years old and have experienced a cardiac arrest outside of the hospital. They should be in a coma when they arrive at the hospital and have had their heart restarted within 45 minutes. Participants will receive close monitoring in the intensive care unit, and their brain activity will be continuously checked to confirm the diagnosis of refractory status epilepticus. It's important to note that patients with certain conditions, such as bleeding in the brain or those who are pregnant, cannot join the study. If you or a loved one qualifies, this trial could offer access to innovative treatments that may improve recovery outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years old
• • 2. Non-traumatic, out-of-hospital cardiac arrest
• • 3. Comatose on admission - defined as not following commands
• • 4. Return of spontaneous circulation (ROSC) within less than 45 minutes
• • 5. Admission to the intensive care unit
• • 6. Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous
• • EEG monitoring within 7 days from ROSC
• Exclusion Criteria:
• • 1. Acute cerebral hemorrhage or infarction
• • 2. Pregnancy
• • 3. Prisoners